[10] Tertomotide Doti N, Mardirossian M, Sandomenico A, Ruvo M, Caporale A (August 2021)
The Endocrine Society's 2020 position statement on peptide therapeutics emphasizes that "the absence of Phase I dose-escalation data for novel peptides like BPC-157 means that any dose recommendation is extrapolated, not validated, and clinicians should err on the side of the lowest effective dose" 19
It also modulates neuroendocrine function, particularly by normalizing melatonin secretion, thereby influencing circadian rhythm regulation and age-related hormonal balance
Acknowledgements We thank Dr
& Ames, B
PMID: 14673993 Fraternale A, Paoletti MF, Casabianca A, Nencioni L, Garaci E, Palamara AT, Magnani M